Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             225 results found
no title author magazine year volume issue page(s) type
1 A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales Hirve, Siddhivinayak
 2011
 29 Supplement 3 p. 5363-5367
5 p.
 article
2 A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings—A randomised blind study Gildea, Sarah
 2011
 29 Supplement 3 p. 9214-9223
10 p.
 article
3 Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice Schneider-Ohrum, Kirsten
 2011
 29 Supplement 3 p. 9081-9092
12 p.
 article
4 A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection Lima, Danielle Malta
 2011
 29 Supplement 3 p. 831-838
8 p.
 article
5 Adolescents’ awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary Marek, Erika
 2011
 29 Supplement 3 p. 8591-8598
8 p.
 article
6 Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques Carroll, Timothy D.
 2011
 29 Supplement 3 p. 931-940
10 p.
 article
7 Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals Bernatchez, Chantale
 2011
 29 Supplement 3 p. 3021-3030
10 p.
 article
8 An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers Madhun, Abdullah S.
 2010
 29 Supplement 3 p. 266-273
8 p.
 article
9 A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness Langley, J.M.
 2011
 29 Supplement 3 p. 1921-1928
8 p.
 article
10 Antibody persistence at 18–20months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China Li, Rong Cheng
 2011
 29 Supplement 3 p. 9337-9344
8 p.
 article
11 Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation Cranage, Martin P.
 2011
 29 Supplement 3 p. 1421-1430
10 p.
 article
12 A pandemic influenza vaccine in India: From strain to sale within 12 months Dhere, Rajeev
 2011
 29 Supplement 3 p. A16-A21
nvt p.
 article
13 A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients Staff, Caroline
 2011
 29 Supplement 3 p. 6817-6822
6 p.
 article
14 A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects Keefer, Michael C.
 2011
 29 Supplement 3 p. 1948-1958
11 p.
 article
15 A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV Somogyi, Eszter
 2011
 29 Supplement 3 p. 744-753
10 p.
 article
16 A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years Tennis, Patricia
 2011
 29 Supplement 3 p. 4947-4952
6 p.
 article
17 A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older Forrest, Bruce D.
 2011
 29 Supplement 3 p. 3633-3639
7 p.
 article
18 A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants Bernstein, David I.
 2011
 29 Supplement 3 p. 7042-7048
7 p.
 article
19 A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1 Koti, Madhuri
 2011
 29 Supplement 3 p. 7905-7912
8 p.
 article
20 Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad Zipursky, Simona
 2011
 29 Supplement 3 p. 5652-5656
5 p.
 article
21 A stable plasmid system for heterologous antigen expression in attenuated Vibrio anguillarum Xiao, Yan
 2011
 29 Supplement 3 p. 6986-6993
8 p.
 article
22 A systematic review of intradermal influenza vaccines Young, Flora
 2011
 29 Supplement 3 p. 8788-8801
14 p.
 article
23 Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age Miller, E. Kathryn
 2011
 29 Supplement 3 p. 3431-3437
7 p.
 article
24 Attenuation of bovine herpesvirus type 1 by deletion of its glycoprotein G and tk genes and protection against virulent viral challenge Zhang, Minmin
 2011
 29 Supplement 3 p. 8943-8950
8 p.
 article
25 Barriers to implementation of the new targeted BCG vaccination in France: A cross sectional study Rossignol, L.
 2011
 29 Supplement 3 p. 5232-5237
6 p.
 article
26 B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon Lima-Junior, J.C.
 2011
 29 Supplement 3 p. 1801-1811
11 p.
 article
27 BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity Keyser, Andrew
 2011
 29 Supplement 3 p. 9308-9315
8 p.
 article
28 Bioprocess optimization for cell culture based influenza vaccine production Aggarwal, Kunal
 2011
 29 Supplement 3 p. 3320-3328
9 p.
 article
29 Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant Ebensen, Thomas
 2011
 29 Supplement 3 p. 5210-5220
11 p.
 article
30 Bone marrow vaccination: A novel approach to enhance antigen specific antitumor immunity Fresnay, Stephanie
 2011
 29 Supplement 3 p. 8599-8605
7 p.
 article
31 Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves Hägglund, Sara
 2011
 29 Supplement 3 p. 8719-8730
12 p.
 article
32 Cancer vaccines and carbohydrate epitopes Heimburg-Molinaro, Jamie
 2011
 29 Supplement 3 p. 8802-8826
25 p.
 article
33 Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines Westdijk, Janny
 2011
 29 Supplement 3 p. 3390-3397
8 p.
 article
34 Chronological study of cytokine transcription in the spleen and lung of chickens after vaccination with serotype 1 Marek's disease vaccines Gimeno, Isabel M.
 2011
 29 Supplement 3 p. 1583-1594
12 p.
 article
35 Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides Denoël, Philippe
 2011
 29 Supplement 3 p. 6451-6453
3 p.
 article
36 Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose Zheng, Hui
 2011
 29 Supplement 3 p. 9098-9103
6 p.
 article
37 Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis Scott, Pippa
 2011
 29 Supplement 3 p. 9711-9721
11 p.
 article
38 Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen Vu, David M.
 2011
 29 Supplement 3 p. 1968-1973
6 p.
 article
39 Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers Van Gessel, Yvonne
 2011
 29 Supplement 3 p. 5925-5931
7 p.
 article
40 Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines Tyo, Karen Richards
 2011
 29 Supplement 3 p. 6686-6694
9 p.
 article
41 Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals Rohani, Md Yasin
 2011
 29 Supplement 3 p. 5688-5693
6 p.
 article
42 Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine Yen, Catherine
 2011
 29 Supplement 3 p. 4151-4155
5 p.
 article
43 Determination of antigenic properties of vaccine derived poliovirus strains Pliaka, Vaia
 2010
 29 Supplement 3 p. 26-33
8 p.
 article
44 Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus) Jadi, R.S.
 2011
 29 Supplement 3 p. 4613-4617
5 p.
 article
45 Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2 Posavad, Christine M.
 2011
 29 Supplement 3 p. 7058-7066
9 p.
 article
46 Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever Osorio, Jorge E.
 2011
 29 Supplement 3 p. 7251-7260
10 p.
 article
47 Difficulties in the prevention of cervical cancer: Adults’ attitudes towards HPV vaccination 3 years after introducing the vaccine in Hungary Marek, Erika
 2011
 29 Supplement 3 p. 5122-5129
8 p.
 article
48 Diphtheria–tetanus–pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau Agergaard, J.
 2011
 29 Supplement 3 p. 487-500
14 p.
 article
49 Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine Somech, Ido
 2011
 29 Supplement 3 p. 4202-4209
8 p.
 article
50 Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa Mothibeli, Kedibone M.
 2011
 29 Supplement 3 p. 2187-2192
6 p.
 article
51 Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates Marsh, Jane W.
 2011
 29 Supplement 3 p. 6049-6058
10 p.
 article
52 Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-α among naïve chronic hepatitis B patients? Alavi-Moghaddam, Mostafa
 2011
 29 Supplement 3 p. 9093-9097
5 p.
 article
53 Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan Fredriksen, B.N.
 2011
 29 Supplement 3 p. 8338-8349
12 p.
 article
54 Economic analysis of the global polio eradication initiative Duintjer Tebbens, Radboud J.
 2010
 29 Supplement 3 p. 334-343
10 p.
 article
55 Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy Boccalini, Sara
 2011
 29 Supplement 3 p. 9521-9528
8 p.
 article
56 Economic evaluation of infant and adolescent hepatitis B vaccination in the UK Siddiqui, M. Ruby
 2011
 29 Supplement 3 p. 466-475
10 p.
 article
57 Editorial Board 2011
 29 Supplement 3 p. CO2-
1 p.
 article
58 Editorial Board 2011
 29 Supplement 3 p. CO2-
1 p.
 article
59 Editorial Board/Aims and Scope 2011
 29 Supplement 3 p. CO2-
1 p.
 article
60 Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand Arnold, Richard
 2011
 29 Supplement 3 p. 7100-7106
7 p.
 article
61 Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine Miller, Elizabeth
 2011
 29 Supplement 3 p. 9127-9131
5 p.
 article
62 Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study Domínguez, Angela
 2011
 29 Supplement 3 p. 9020-9025
6 p.
 article
63 Effect of GonaCon™ vaccine on black-tailed prairie dogs: Immune response and health effects Yoder, Christi A.
 2010
 29 Supplement 3 p. 233-239
7 p.
 article
64 Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal Shuaibu, M.N.
 2011
 29 Supplement 3 p. 3239-3247
9 p.
 article
65 Effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the immune responses to Newcastle disease vaccine in chickens Zhai, Lijuan
 2011
 29 Supplement 3 p. 5007-5014
8 p.
 article
66 Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines Carstens, Myrra G.
 2011
 29 Supplement 3 p. 4761-4770
10 p.
 article
67 Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers Chakvetadze, Catherine
 2011
 29 Supplement 3 p. 2846-2849
4 p.
 article
68 Enhanced immune sera and vaccine: Safe approach to treat scorpion envenoming Lila, Boussag-Abib
 2011
 29 Supplement 3 p. 8951-8959
9 p.
 article
69 Evaluation of cell-mediated immune responses to two BCG vaccination regimes in young children in South Korea Lee, Hyejon
 2011
 29 Supplement 3 p. 6564-6571
8 p.
 article
70 Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products Parveen, Seema
 2011
 29 Supplement 3 p. 8012-8023
12 p.
 article
71 Evaluation of novel fusion proteins derived from extracellular matrix binding domains of LigB as vaccine candidates against leptospirosis in a hamster model Cao, Yongguo
 2011
 29 Supplement 3 p. 7379-7386
8 p.
 article
72 Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains Shi, Xing-Ming
 2011
 29 Supplement 3 p. 1576-1582
7 p.
 article
73 Evaluation of the reliability, validity and practicality of 3 measures of acute pain in infants undergoing immunization injections Taddio, Anna
 2011
 29 Supplement 3 p. 1390-1394
5 p.
 article
74 Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial Barreto, Mauricio L.
 2011
 29 Supplement 3 p. 4875-4877
3 p.
 article
75 Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis Schneider, Karen
 2011
 29 Supplement 3 p. 6086-6091
6 p.
 article
76 Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline Davis, Matthew M.
 2011
 29 Supplement 3 p. 9414-9416
3 p.
 article
77 Financing and systems barriers to seasonal influenza vaccine delivery in community settings Penfold, Robert B.
 2011
 29 Supplement 3 p. 9632-9639
8 p.
 article
78 French healthcare workers in geriatric healthcare settings staunchly opposed to influenza vaccination: The VESTA study Gavazzi, Gaëtan
 2011
 29 Supplement 3 p. 1611-1616
6 p.
 article
79 Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses Mantel, N.
 2011
 29 Supplement 3 p. 6629-6635
7 p.
 article
80 Guillain–Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition Choe, Young June
 2011
 29 Supplement 3 p. 2066-2070
5 p.
 article
81 Guillain–Barré Syndrome in India: Population-based validation of the Brighton criteria Mateen, Farrah J.
 2011
 29 Supplement 3 p. 9697-9701
5 p.
 article
82 Hepatitis B immunity and vaccination coverage among young adult males in the Air Force in South Brazil Passos, Ana Maria
 2011
 29 Supplement 3 p. 9284-9288
5 p.
 article
83 Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009 Lu, Peng-jun
 2011
 29 Supplement 3 p. 7049-7057
9 p.
 article
84 High burden of tick-borne encephalitis in Slovenia—Challenge for vaccination policy Grgič-Vitek, Marta
 2011
 29 Supplement 3 p. 5178-5183
6 p.
 article
85 Highly effective generic adjuvant systems for orphan or poverty-related vaccines Rao, Mangala
 2011
 29 Supplement 3 p. 873-877
5 p.
 article
86 H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals Lee, Dong-Hun
 2011
 29 Supplement 3 p. 4003-4007
5 p.
 article
87 Hospital initiation of a vaccinal schedule improves the long-term vaccinal coverage of ex-preterm children Denizot, S.
 2011
 29 Supplement 3 p. 382-386
5 p.
 article
88 HPV vaccination in France: Uptake, costs and issues for the National Health Insurance Fagot, Jean-Paul
 2011
 29 Supplement 3 p. 3610-3616
7 p.
 article
89 Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital Schluterman, Nicholas H.
 2011
 29 Supplement 3 p. 3767-3772
6 p.
 article
90 Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA Santamaria, Raquel
 2011
 29 Supplement 3 p. 8689-8695
7 p.
 article
91 Identification and characterization of a cross-neutralization epitope of Enterovirus 71 Liu, Chia-Chyi
 2011
 29 Supplement 3 p. 4362-4372
11 p.
 article
92 Identification of a new protective antigen of Bordetella pertussis Alvarez Hayes, Jimena
 2011
 29 Supplement 3 p. 8731-8739
9 p.
 article
93 Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins Hendrikx, Lotte H.
 2011
 29 Supplement 3 p. 1431-1437
7 p.
 article
94 Immune response of varicella vaccinees to different varicella-zoster virus genotypes Sauerbrei, A.
 2011
 29 Supplement 3 p. 3873-3877
5 p.
 article
95 Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates Capone, Stefania
 2010
 29 Supplement 3 p. 256-265
10 p.
 article
96 Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection Liu, Min
 2011
 29 Supplement 3 p. 1745-1753
9 p.
 article
97 Immunization of female BALB/c mice with Neospora cyclophilin and/or NcSRS2 elicits specific antibody response and prevents against challenge infection by Neospora caninum Tuo, Wenbin
 2011
 29 Supplement 3 p. 2392-2399
8 p.
 article
98 Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea Lee, Soo Young
 2011
 29 Supplement 3 p. 1551-1557
7 p.
 article
99 Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study Bernstein, Henry H.
 2011
 29 Supplement 3 p. 2212-2221
10 p.
 article
100 Immunogenicity and safety of a Haemophilus influenzae B (Hib)–hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants Lee, Andrew W.
 2011
 29 Supplement 3 p. 7942-7948
7 p.
 article
101 Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses Rümke, H.C.
 2011
 29 Supplement 3 p. 3842-3849
8 p.
 article
102 Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study Rusnak, Janice M.
 2011
 29 Supplement 3 p. 3222-3229
8 p.
 article
103 Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China Li, Rong Cheng
 2011
 29 Supplement 3 p. 1913-1920
8 p.
 article
104 Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents Garcia-Sicilia, J.
 2011
 29 Supplement 3 p. 4353-4361
9 p.
 article
105 Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study Grimprel, Emmanuel
 2011
 29 Supplement 3 p. 7370-7378
9 p.
 article
106 Immunogenicity and safety of intradermal influenza vaccine in children Esposito, Susanna
 2011
 29 Supplement 3 p. 7606-7610
5 p.
 article
107 Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine Gimenez-Sanchez, Francisco
 2011
 29 Supplement 3 p. 6042-6048
7 p.
 article
108 Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys Koeberling, Oliver
 2011
 29 Supplement 3 p. 4728-4734
7 p.
 article
109 Immunogenicity of hepatitis B vaccine among hemodialysis patients: Effect of revaccination of non-responders and duration of protection Chaves, Sandra S.
 2011
 29 Supplement 3 p. 9618-9623
6 p.
 article
110 Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration Cherif, Mahamoud Sama
 2011
 29 Supplement 3 p. 9038-9050
13 p.
 article
111 Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation Dolter, Karen E.
 2011
 29 Supplement 3 p. 795-803
9 p.
 article
112 Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age Wilson, Kumanan
 2011
 29 Supplement 3 p. 8267-8274
8 p.
 article
113 Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges Hanquet, Germaine
 2011
 29 Supplement 3 p. 2856-2864
9 p.
 article
114 Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age Hendrikx, Lotte H.
 2011
 29 Supplement 3 p. 5725-5730
6 p.
 article
115 Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage Prymula, Roman
 2011
 29 Supplement 3 p. 1959-1967
9 p.
 article
116 Implementation and evaluation of the Reaching Every District (RED) strategy in Assam, India, 2005–2008 Ryman, Tove K.
 2011
 29 Supplement 3 p. 2555-2560
6 p.
 article
117 Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice Wu, Juan
 2011
 29 Supplement 3 p. 7624-7630
7 p.
 article
118 Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response Moraes, Mauro Pires
 2011
 29 Supplement 3 p. 9431-9440
10 p.
 article
119 In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization Zhao, Qinjian
 2011
 29 Supplement 3 p. 7936-7941
6 p.
 article
120 Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) Taylor, David N.
 2011
 29 Supplement 3 p. 4897-4902
6 p.
 article
121 Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial Plennevaux, Eric
 2011
 29 Supplement 3 p. 1569-1575
7 p.
 article
122 Influenza vaccine coverage, influenza-associated morbidity and all-cause mortality in Catalonia (Spain) Muñoz, M. Pilar
 2011
 29 Supplement 3 p. 5047-5052
6 p.
 article
123 Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results Belongia, Edward A.
 2011
 29 Supplement 3 p. 6558-6563
6 p.
 article
124 Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice Madhun, Abdullah S.
 2011
 29 Supplement 3 p. 4973-4982
10 p.
 article
125 Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice Zhang, Ailian
 2011
 29 Supplement 3 p. 6785-6792
8 p.
 article
126 Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality Rodríguez, Mª Angeles Gutiérrez
 2011
 29 Supplement 3 p. 5740-5746
7 p.
 article
127 Invasive pneumococcal disease in Catalonian elderly people, 2002–2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era Vila-Corcoles, Angel
 2011
 29 Supplement 3 p. 7430-7434
5 p.
 article
128 Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination Parretta, Elisabetta
 2011
 29 Supplement 3 p. 3708-3713
6 p.
 article
129 Kinetics of maternal antibodies against rubella and varicella in infants Leuridan, E.
 2011
 29 Supplement 3 p. 2222-2226
5 p.
 article
130 Malaria vaccine candidate: Design of a multivalent subunit α-helical coiled coil poly-epitope Olugbile, Sope
 2011
 29 Supplement 3 p. 7090-7099
10 p.
 article
131 Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers Rynkiewicz, Dianna
 2011
 29 Supplement 3 p. 6313-6320
8 p.
 article
132 Maternal antibodies to rotavirus: Could they interfere with live rotavirus vaccines in developing countries? Chan, J.
 2011
 29 Supplement 3 p. 1242-1247
6 p.
 article
133 Measles susceptibility in children in Karachi, Pakistan Sheikh, Sana
 2011
 29 Supplement 3 p. 3419-3423
5 p.
 article
134 Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US Shea, K.M.
 2011
 29 Supplement 3 p. 8042-8048
7 p.
 article
135 Mother–infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination Holmlund, Emma
 2011
 29 Supplement 3 p. 4565-4575
11 p.
 article
136 Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1–43/IL-10 cDNA Hara, Hideo
 2011
 29 Supplement 3 p. 7474-7482
9 p.
 article
137 MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes Mendes, Érica A.
 2011
 29 Supplement 3 p. 4476-4484
9 p.
 article
138 Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx Kodama, Satoru
 2011
 29 Supplement 3 p. 1881-1890
10 p.
 article
139 “Once I begin to participate, people will run away from me”: Understanding stigma as a barrier to HIV vaccine research participation in Kenya Nyblade, Laura
 2011
 29 Supplement 3 p. 8924-8928
5 p.
 article
140 Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age Russell, F.M.
 2011
 29 Supplement 3 p. 535-544
10 p.
 article
141 Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans Wu, Jiang
 2011
 29 Supplement 3 p. 1009-1016
8 p.
 article
142 Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate Asensio, Cristian J.A.
 2011
 29 Supplement 3 p. 1649-1656
8 p.
 article
143 Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009 Williams, S. Elizabeth
 2011
 29 Supplement 3 p. 6920-6927
8 p.
 article
144 Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination Lagler, Heimo
 2011
 29 Supplement 3 p. 6888-6893
6 p.
 article
145 Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009 Kelly, Heath A.
 2011
 29 Supplement 3 p. 6419-6426
8 p.
 article
146 Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs Tarradas, Joan
 2011
 29 Supplement 3 p. 4422-4429
8 p.
 article
147 Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations—A population based study of 969,519 vaccination events Wilson, Kumanan
 2011
 29 Supplement 3 p. 3746-3752
7 p.
 article
148 Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine Weston, Wayde
 2011
 29 Supplement 3 p. 8483-8486
4 p.
 article
149 Pertussis after end of a mass vaccination project—End of the “vaccination honey-moon” Trollfors, Birger
 2011
 29 Supplement 3 p. 2444-2450
7 p.
 article
150 Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats López, Yulieé
 2011
 29 Supplement 3 p. 3596-3599
4 p.
 article
151 Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine Gadzinowski, Janusz
 2011
 29 Supplement 3 p. 2947-2955
9 p.
 article
152 Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance van den Biggelaar, Anita H.J.
 2011
 29 Supplement 3 p. 5414-5420
7 p.
 article
153 Pneumococcal disease manifestation in children before and after vaccination: What's new? Andrade, Ana Lucia
 2011
 29 Supplement 3 p. C2-C14
nvt p.
 article
154 Polyfunctional analysis of Gag and Nef specific CD8+ T-cell responses in HIV-1 infected Indian individuals Mendiratta, Sanjay
 2011
 29 Supplement 3 p. 1150-1158
9 p.
 article
155 Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model Skinner, Julie M.
 2011
 29 Supplement 3 p. 8870-8876
7 p.
 article
156 Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes Niu, Liguo
 2011
 29 Supplement 3 p. 2110-2119
10 p.
 article
157 Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States Wang, Xin
 2011
 29 Supplement 3 p. 4739-4744
6 p.
 article
158 Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy Lao-araya, Mongkol
 2011
 29 Supplement 3 p. 3977-3981
5 p.
 article
159 Prevenar experience Arguedas, Adriano
 2011
 29 Supplement 3 p. C26-C34
nvt p.
 article
160 Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies Canfell, Karen
 2011
 29 Supplement 3 p. 2487-2494
8 p.
 article
161 Prevention of pneumococcal disease through vaccination Gentile, Angela
 2011
 29 Supplement 3 p. C15-C25
nvt p.
 article
162 Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling Partidos, Charalambos D.
 2011
 29 Supplement 3 p. 3067-3073
7 p.
 article
163 Productive infection of human hepatocellular carcinoma cells by porcine circovirus type 1 Beach, Nathan M.
 2011
 29 Supplement 3 p. 7303-7306
4 p.
 article
164 Promoter control over foreign antigen expression in a murine cytomegalovirus vaccine vector Cunningham, Paula T.
 2010
 29 Supplement 3 p. 141-151
11 p.
 article
165 Prospective pertussis surveillance in Switzerland, 1991–2006 Wymann, Monica N.
 2011
 29 Supplement 3 p. 2058-2065
8 p.
 article
166 Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus Xue, Wenzhi
 2011
 29 Supplement 3 p. 4657-4662
6 p.
 article
167 Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate Windish, Hillarie Plessner
 2011
 29 Supplement 3 p. 7842-7848
7 p.
 article
168 Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine Ashraf, Shamaila
 2011
 29 Supplement 3 p. 3990-4002
13 p.
 article
169 Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression Bunupuradah, Torsak
 2011
 29 Supplement 3 p. 2962-2967
6 p.
 article
170 Rapid, non-invasive imaging of alphaviral brain infection: Reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals Patterson, Michael
 2011
 29 Supplement 3 p. 9345-9351
7 p.
 article
171 Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults Leeb, Alan
 2011
 29 Supplement 3 p. 7920-7924
5 p.
 article
172 Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4–6 years old Quinn, Patrick
 2011
 29 Supplement 3 p. 4230-4237
8 p.
 article
173 Recurrent apnoea post immunisation: Informing re-immunisation policy Clifford, Vanessa
 2011
 29 Supplement 3 p. 5681-5687
7 p.
 article
174 Regional patterns of mortality during the 1918 influenza pandemic in Newfoundland Sattenspiel, Lisa
 2011
 29 Supplement 3 p. B33-B37
nvt p.
 article
175 Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17–18 February 2011 Girard, Marc P.
 2011
 29 Supplement 3 p. 7579-7586
8 p.
 article
176 Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response DiNapoli, Joshua M.
 2010
 29 Supplement 3 p. 17-25
9 p.
 article
177 Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: Towards an in vitro assay for vaccine immunogenicity Hoefnagel, Marcel H.N.
 2011
 29 Supplement 3 p. 5114-5121
8 p.
 article
178 Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study Stowe, Julia
 2011
 29 Supplement 3 p. 9467-9472
6 p.
 article
179 Safety and immunogenicity of a candidate parvovirus B19 vaccine Bernstein, David I.
 2011
 29 Supplement 3 p. 7357-7363
7 p.
 article
180 Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) García, Felipe
 2011
 29 Supplement 3 p. 8309-8316
8 p.
 article
181 Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults Turley, Christine B.
 2011
 29 Supplement 3 p. 5145-5152
8 p.
 article
182 Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age Diaz-Mitoma, Francisco
 2011
 29 Supplement 3 p. 1324-1331
8 p.
 article
183 Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis Wang, Ling-yun
 2011
 29 Supplement 3 p. 2679-2681
3 p.
 article
184 Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh Rahman, Kazi Mizanur
 2011
 29 Supplement 3 p. 1347-1354
8 p.
 article
185 Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus Satoh, Ryoichi
 2011
 29 Supplement 3 p. 1791-1800
10 p.
 article
186 Seasonal influenza vaccination in adults: Practice and attitudes about collaborative delivery with community vaccinators Hurley, Laura P.
 2011
 29 Supplement 3 p. 8649-8655
7 p.
 article
187 Seroprevalence of varicella zoster virus among pregnant women in Hong Kong: Comparison with self-reported history Fung, Linda Wen Ying
 2011
 29 Supplement 3 p. 8186-8188
3 p.
 article
188 Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000–2007 Menezes, Ana Paula de O.
 2011
 29 Supplement 3 p. 1139-1144
6 p.
 article
189 Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months Russell, F.M.
 2011
 29 Supplement 3 p. 4499-4506
8 p.
 article
190 Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease Yildirim, Inci
 2010
 29 Supplement 3 p. 283-288
6 p.
 article
191 SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine Clifford, Holly D.
 2011
 29 Supplement 3 p. 5407-5413
7 p.
 article
192 Smallpox eradication in Bangladesh, 1972–1976 Foster, Stanley O.
 2011
 29 Supplement 3 p. D22-D29
nvt p.
 article
193 Stability of RNA virus attenuation approaches Kenney, Joan L.
 2011
 29 Supplement 3 p. 2230-2234
5 p.
 article
194 Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative Jauregui, Barbara
 2011
 29 Supplement 3 p. 1099-1106
8 p.
 article
195 Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era Kendall, Brian A.
 2011
 29 Supplement 3 p. 9123-9126
4 p.
 article
196 Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice Amuguni, J. Hellen
 2011
 29 Supplement 3 p. 4778-4784
7 p.
 article
197 Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine Zhang, Wei
 2011
 29 Supplement 3 p. 6276-6282
7 p.
 article
198 T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep Rojas, José-Manuel
 2011
 29 Supplement 3 p. 6848-6857
10 p.
 article
199 Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants Verhaegh, Suzanne J.C.
 2011
 29 Supplement 3 p. 5603-5610
8 p.
 article
200 Ten years of Hib vaccination in Italy: Prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance Giufrè, Maria
 2011
 29 Supplement 3 p. 3857-3862
6 p.
 article
201 The current status of invasive pneumococcal disease in Poland Skoczyńska, Anna
 2011
 29 Supplement 3 p. 2199-2205
7 p.
 article
202 The factor H-binding fragment of PspC as a vaccine antigen for the induction of protective humoral immunity against experimental pneumococcal sepsis Ricci, Susanna
 2011
 29 Supplement 3 p. 8241-8249
9 p.
 article
203 The future of pneumococcal disease prevention Rodgers, Gail L.
 2011
 29 Supplement 3 p. C43-C48
nvt p.
 article
204 The global polio eradication initiative: Lessons learned and prospects for success Aylward, Bruce
 2011
 29 Supplement 3 p. D80-D85
nvt p.
 article
205 The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children Thanee, Chareeya
 2011
 29 Supplement 3 p. 5886-5891
6 p.
 article
206 The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children Okike, Ifeanyichukwu O.
 2011
 29 Supplement 3 p. 6636-6640
5 p.
 article
207 The immunogenicity of pneumococcal polysaccharides in infants and children: A meta-regression Laferriere, Craig
 2011
 29 Supplement 3 p. 6838-6847
10 p.
 article
208 The 1918 influenza pandemic in Florianopolis: A subtropical city in Brazil Alonso, Wladimir J.
 2011
 29 Supplement 3 p. B16-B20
nvt p.
 article
209 The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response Seyoum, Beza
 2011
 29 Supplement 3 p. 8002-8011
10 p.
 article
210 The optimal number of routine vaccines to order at health clinics in low or middle income countries Rajgopal, Jayant
 2011
 29 Supplement 3 p. 5512-5518
7 p.
 article
211 The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children Palma, Paolo
 2011
 29 Supplement 3 p. 6810-6816
7 p.
 article
212 The perils of using annual all-cause mortality data to estimate pandemic influenza burden Andreasen, Viggo
 2011
 29 Supplement 3 p. B49-B55
nvt p.
 article
213 The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia Smith, Megan A.
 2011
 29 Supplement 3 p. 9112-9122
11 p.
 article
214 Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies Dalgleish, Angus G.
 2011
 29 Supplement 3 p. 8501-8505
5 p.
 article
215 The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep Maggioli, Gabriela
 2011
 29 Supplement 3 p. 9057-9063
7 p.
 article
216 Transmission of mumps virus from mumps-vaccinated individuals to close contacts Fanoy, Ewout B.
 2011
 29 Supplement 3 p. 9551-9556
6 p.
 article
217 Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model Kollessery, Gayathri
 2011
 29 Supplement 3 p. 5904-5910
7 p.
 article
218 Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in Denmark Harder, Katja Majlund
 2011
 29 Supplement 3 p. 9303-9307
5 p.
 article
219 Updated aluminum pharmacokinetics following infant exposures through diet and vaccination Mitkus, Robert J.
 2011
 29 Supplement 3 p. 9538-9543
6 p.
 article
220 Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country Biai, Sidu
 2011
 29 Supplement 3 p. 3662-3669
8 p.
 article
221 Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus Loeffen, W.L.A.
 2011
 29 Supplement 3 p. 1545-1550
6 p.
 article
222 Validity and reliability of a survey to identify vaccine-hesitant parents Opel, Douglas J.
 2011
 29 Supplement 3 p. 6598-6605
8 p.
 article
223 Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media Seppälä, Elina
 2011
 29 Supplement 3 p. 8615-8618
4 p.
 article
224 Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice Chauhan, Neelima B.
 2011
 29 Supplement 3 p. 7631-7637
7 p.
 article
225 Worsening disparities in HPV vaccine utilization among 19–26 year old women Dempsey, Amanda
 2011
 29 Supplement 3 p. 528-534
7 p.
 article
                             225 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands